Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIMAvax-EGF Vaccine in High Risk Lung Cancer and Survivors
NCT04298606Phase 1Completed
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Nov 2021
- Primary completion
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes, Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cimavax egf in lung cancer, sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoints: Percentage of participants with antibody titers >= 1:4000 in response to vaccination, Molecular biomarker analysis and 1 more. Started Nov 2021; status: completed.
02
Drugs
cimavax egf
03
Conditions
lung cancer
Beyond the preview
Go deeper on NCT04298606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04298606.